Orchid Pharma Ltd
Orchid Pharma Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain. Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
From Orchid Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain.
- Recent quarters showed 15%-20% volume growth; however, price corrections in key products have muted topline revenue growth.
- The company is cautious about maintaining the same 20% year-on-year growth in FY '25 due to sharp spot price corrections, mainly in oral products.
- Long-term growth remains positive with sustained volume increases and operational excellence.
- New product launches like Enmetazobactam and Cefiderocol (commissioned by December 2026) are expected to contribute to future growth, though Cefiderocol revenue is anticipated beyond 2 years.
2 more points from Orchid Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Orchid Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No changes in capex timelines; projects on track as planned (Page 17).
- Capex ongoing for 7ACA and Cefiderocol lines with no new expansion planned in the sterile business for the near future (Pages 10, 17).
- Sterile capacity expanded last year and expected to serve well for the next couple of years (Page 10).
- Cefiderocol project under construction; commissioning expected by November-December 2026 (Page 8).
- 7ACA project execution continues as planned despite delays; no material changes in PLI incentive or duration (Pages 8-9).
2 more points from Orchid Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Orchid Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Orchid Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Orchid Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹304 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Orchid Pharma Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Orchid Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Orchid Pharma Ltd Q3 FY25 results?
Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain. Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a neutral. The stock trades at a P/E of 348.0 with a market cap of ₹9,439 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
No changes in capex timelines; projects on track as planned (Page 17).
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.